Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), tells Proactive's Andrew Scott they've initiated a rolling submission of a new drug application to the US Food & Drug Administration for iclaprim.
The new drug application (NDA) for their flagship next-generation antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) is expected to be completed during the second quarter of 2018.
Meet ANGLE plc, Faron Pharmaceuticals Ltd, Alliance Pharma plc, Clinigen Group PLC and Avacta Group Plc at our event,London, 05 April 2018.Register here >>